Post-transplant pegylated interferon alfa-2a maintenance in myelofibrosis

Current understanding

Pegylated interferon alfa-2a is being explored as a novel post-alloHCT maintenance/consolidation strategy in primary or secondary myelofibrosis, with a Phase 1 dose de-escalation study currently defining safety and the recommended phase 2 dose (trial-early evidence). This is execution-layer: it does not shift the upstream decision of whether or when to transplant, but adds a candidate maintenance option alongside HMAs for relapse prevention in MF. Efficacy data are not yet available.

Evidence log

• 2026-06-23 — A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant: cross-connection with mrd-guided-post-transplant-maintenance: PegINFa maintenance is another candidate post-HCT maintenance modality that could plausibly be slotted into an MRD-directed assignment framework for MPN/MF patients. (novelty: 3)
• 2026-06-04 — AlloHCT With PegINFa for Myelofibrosis: cross-connection with post-transplant-maintenance-hma: Both represent post-alloHCT maintenance strategies for MPN/MF; pegINFa (immunomodulatory) and oral decitabine/cedazuridine (hypomethylating) are mechanistically distinct candidates competing for the same post-transplant relapse-prevention niche. (novelty: 4)

Open questions

Related